Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Phase 3 study of Ixiaro for Japanese encephalitis
2009-015588-15Phase 3
- Sponsor
- Intercell AG
- Start
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Intercell AG. Primary endpoint: Serious adverse events and medically attended adverse events.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2009-015588-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015588-15.